Loading…
← CockpitCompetitor Analysis › RYTM Rhythm Pharmaceuticals, Inc.Open in the cockpit ↗

Rhythm Pharmaceuticals, Inc.RYTMCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling Imcivree, a drug for rare genetic obesity disorders caused by defects in the MC4R pathway.

Momentum leader 92
Mkt cap
$8.25B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$207M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-163.2 pp
WACC 15.8%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$119.04
1D+2.1%
1W+6.1%
1M+32.0%
3M+9.3%
6M+31.3%
YTD+11.2%
1Y+18.2%
ATR %5.3%
Beta1.18
52w lowhigh2.6% off high

What Rhythm Pharmaceuticals does

Biotech selling Imcivree, a drug for rare genetic obesity disorders caused by defects in the MC4R pathway.

Sells Imcivree, a daily injection, through specialty pharmacies to patients who first need a genetic diagnosis, so sales depend on finding eligible patients and winning insurers' coverage, and each stays on treatment for years. Orphan status, extra years of exclusivity for rare diseases, protects it. It is pursuing the wider group with hypothalamic obesity.

Products and services

  • Imcivree (setmelanotide)
  • MC4R pathway pipeline

Customers

  • Endocrinologists
  • Obesity/genetics specialists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Rare genetic/hypothalamic obesity

What could go right

  • Broader genetic testing driving diagnosis and prescriptions
  • International Imcivree launches

What could go wrong

  • Very small addressable patient population
  • Broader GLP-1 obesity drugs indirectly competing for attention

Moat: narrow (IP / patents, regulatory licence). Only approved therapy targeting specific genetic causes of severe obesity, protected by patents and orphan exclusivity.

Headquarters: Boston, Massachusetts, United States · Founded: 2008 · Employees: 414

Named competitors

Rhythm Pharmaceuticals at a glance

Size Rhythm Pharmaceuticals (RYTM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $8.25B, the 871st largest of 3,085 United States companies the cockpit tracks. Shares closed at $119.04 on 18 Nov 2026.

Performance Over six months the shares gained 31.3%, against +12.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 61.0% over the last twelve months (peer median +15.3%); the operating margin is -66.7% (peer median 15.4%).

Valuation It trades at 29.0× enterprise value to sales against a peer median of 4.8× (3rd most expensive of 19).

Capital Return on invested capital runs 163.2 points below its cost of capital (15.8% WACC).

Short interest Short interest is 16.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026RYTM 132Peer median 113
Six months, rebased to 100: Rhythm Pharmaceuticals against the median of its 20 peers (local-currency closes).

Rhythm Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$281M$190M$130M$77.4M$23.6M
Revenue growth—+46%+68%+228%—
Gross profit$248M$170M$116M$67.2M$20.6M
EBITDA-$186M-$191M-$264M-$183M-$178M
Net income-$194M-$197M-$261M-$185M-$181M
Free cash flow-$83.2M-$117M-$114M-$136M-$174M
Capital expenditure$1.45M$41.0M$40.5M$5.71M$4.28M
Total debt$106M$243M$257M$107M$77.8M

Quarterly statements and history in the cockpit →

Rhythm Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%2607PTGX4151PRAXGLENMARKALK-BALKS2196AMRXGRFKNSAHLUN-ACORTMDGL002821CYTKIBRXSYRE3759RYTM6-month return →1-month return →
Up and to the right = strong over both horizons. Rhythm Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×20×40×60×2607PTGX4151GLENMARKALK-BKNSACORTMDGLCYTKIBRXRYTMRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rhythm Pharmaceuticals is the large dot.

Rhythm Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (RYTM vs NOVO-B.CO vs LLY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Rhythm Pharmaceuticals RYTM$8.25B+31%+61%-67%29.0×n/a
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%

How Rhythm Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rhythm Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureRYTMPeer medianRank in peer set
1-month return+32.0%+2.2%highest of 21
6-month return+31.3%+12.4%6th highest of 21
Distance from 52-week high-2.6%-13.6%4th highest of 21
Revenue growth (TTM)+61.0%+15.3%4th highest of 20
Operating margin-66.7%15.4%3rd lowest of 19
EV / Sales29.0×4.8×3rd most expensive of 19
ROIC minus cost of capital-163.2 pp+2.9 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%29.0×n/an/a
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%0.3×-9.7%+7.4%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%13.6×17.5%+10.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%2.1×-4.7%+9.3%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%2.2×19.9%+5.8%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%7.3×10.4%+45.5%
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%2.6×-6.6%+6.6%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%7.3×23.9%+16.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%6.0×n/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%5.7×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%64.3×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%44.3×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%4.4×n/an/a

Questions

Who are Rhythm Pharmaceuticals's main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY), Saniona (private or unlisted), Soleno Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Shanghai Pharmaceuticals (2607.HK), Protagonist Therapeutics (PTGX), Kyowa Kirin (4151.T), Praxis Precision Medicines (PRAX), Glenmark Pharmaceuticals (GLENMARK.NS), ALK-abello A/S (ALK-B.CO).
Is Rhythm Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 29.0× against a peer median of 4.8×, 3rd most expensive of 19 in its peer set.
How has Rhythm Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +31.3% against +12.4% for the median peer; over one year +18.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.